ICAN OBTAINS COPIES OF CLINICAL TRIAL RELIED UPON TO LICENSE MMR VACCINE WHICH REVEAL THAT IT SHOULD NEVER HAVE BEEN LICENSED
Merck sells the only measles, mumps, and rubella vaccine in the United States, trade named M-M-R-II (MMR-II). MMR-II is produced by growing viruses on biological medium, including human diploid lung fibroblasts from an aborted fetus, and was licensed by the FDA in 1978 for people aged 12 months and older.
Prior to FDA licensure of a new experimental vaccines, such as MMR-II, they are expected to undergo long-term placebo-controlled clinical trials with typically tens of thousands of participants to assure their safety.
To evaluate whether Merck met any of these criteria, ICAN, through its attorneys, demanded on August 20, 2018 that the FDA produce copies of all the clinical trial reports relied upon to license Merck’s MMR-II vaccine. The FDA eventually, on March 27, 2019 produced to ICAN copies of the clinical trial reports for this vaccine, totaling 215 pages.
What do these documents show? They show that this product should never have been licensed.
It is also worth pointing out that the first vaccine for measles was licensed in the United States in 1963 and, according to the CDC, the mortality rate from measles declined by over 98% between 1900 and 1962. In the years leading up to 1963 (when no measles vaccine existed), the CDC reported a total of approximately 400 deaths from measles per year in the United States during a time when virtually every American had measles, reflecting an annual death rate from measles of 1 in 500,000 Americans prior to the introduction of the measles vaccine.